Suppr超能文献

乌本苷 C 末端水解酶 L1 与院外心脏骤停。

Ubiquitin C-terminal hydrolase L1 after out-of-hospital cardiac arrest.

机构信息

Department of Anaesthesiology and Intensive Care, Kuopio University Hospital, Kuopio, Finland.

University of Eastern Finland, Kuopio, Finland.

出版信息

Acta Anaesthesiol Scand. 2023 Aug;67(7):964-971. doi: 10.1111/aas.14257. Epub 2023 Apr 28.

Abstract

BACKGROUND

We studied the prognostic ability of serum ubiquitin C-terminal hydrolase L1 (UCH-L1) after out-of-hospital cardiac arrest (OHCA), compared to that of neuron-specific enolase (NSE).

METHODS

In this post-hoc analysis of the FINNRESUSCI study, we measured serum concentrations of UCH-L1 in 249 OHCA patients treated in 21 Finnish intensive care units in 2010-2011. We evaluated the ability of UCH-L1 to predict unfavourable outcome at 12 months (defined as cerebral performance category 3-5) by assessing the area under the receiver operating characteristic curve (AUROC), in comparison with NSE.

RESULTS

The concentrations of UCH-L1 were higher in patients with unfavourable outcome than for those with favourable outcome: median concentration 10.8 ng/mL (interquartile range, 7.5-18.5 ng/mL) versus 7.8 ng/mL (5.9-11.8 ng/mL) at 24 h (p < .001), and 16.2 ng/mL (12.2-27.7 ng/mL) versus 11.5 ng/mL (9.0-17.2 ng/mL) (p < .001) at 48 h after OHCA. For UCH-L1 as a 12-month outcome predictor, the AUROC was 0.66 (95% confidence interval, 0.60-0.73) at 24 h and 0.66 (0.59-0.74) at 48 h. For NSE, the AUROC was 0.66 (0.59-0.73) at 24 h and 0.72 (0.65-0.80) at 48 h. The prognostic ability of UCH-L1 was not different from that of NSE at 24 h (p = .82) and at 48 h (p = .23).

CONCLUSION

Concentrations of UCH-L1 in serum were higher in patients with unfavourable outcome than in those with favourable outcome. However, the ability of UCH-L1 to predict unfavourable outcome after OHCA was only moderate and not superior to that of NSE.

摘要

背景

我们研究了血清泛素羧基末端水解酶 L1(UCH-L1)在院外心脏骤停(OHCA)后的预后能力,并与神经元特异性烯醇化酶(NSE)进行了比较。

方法

在 FINNRESUSCI 研究的事后分析中,我们测量了 2010-2011 年在芬兰 21 个重症监护病房治疗的 249 例 OHCA 患者的血清 UCH-L1 浓度。我们通过评估受试者工作特征曲线(ROC)下面积(AUROC)来评估 UCH-L1 在 12 个月时预测不良预后(定义为脑功能预后分类 3-5)的能力,与 NSE 进行比较。

结果

与预后良好的患者相比,预后不良的患者 UCH-L1 浓度更高:24 小时时,中位数浓度为 10.8ng/mL(四分位距,7.5-18.5ng/mL)比 7.8ng/mL(5.9-11.8ng/mL)(p<0.001),48 小时时为 16.2ng/mL(12.2-27.7ng/mL)比 11.5ng/mL(9.0-17.2ng/mL)(p<0.001)。对于 UCH-L1 作为 12 个月的预后预测因子,24 小时时的 AUROC 为 0.66(95%置信区间,0.60-0.73),48 小时时为 0.66(0.59-0.74)。对于 NSE,24 小时时的 AUROC 为 0.66(0.59-0.73),48 小时时为 0.72(0.65-0.80)。在 24 小时(p=0.82)和 48 小时(p=0.23)时,UCH-L1 的预后能力与 NSE 无差异。

结论

预后不良患者的血清 UCH-L1 浓度高于预后良好的患者。然而,UCH-L1 预测 OHCA 后不良预后的能力仅为中等,并不优于 NSE。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验